Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.IMUX · Entity 6306 | Chief Operating Officer | March 01, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date March 01, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.72 · Expires 2031-03-01 | Direct | 45,000 |
Reported balance
After 2021-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-01 · Grant · Acquired 45,000 · Balance 45,000 F1: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 2, 2021 21:31 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 45,000 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001193805-21-000308 · e620343_4-groppel.xml · derivative · entry 1 Groeppel Manfred · CIK 0001773674 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-03-01 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:06 UTC | IMMUNIC, INC. IMUX · Entity 6306 | SaleCommon Stock | 650 | $15.62 | $10,154.89 |
DisclosureSEC source: 0001193805-20-000880 · e619747_4-groppel.xml · nonDerivative · entry 2 Groeppel Manfred · CIK 0001773674 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 278,830 F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted in connection with certain tax liabilities related to the issuance of shares in the April 2019 exchange transaction between the Issuer (then known as Vital Therapies, Inc.) and Immunic AG. F2 · ownership.nature: The Reporting Person is Director of Groeppel Investments UG (haftungsbeschrankt), which is the record holder of 278,830 shares of common stock of the Issuer, and exercises voting and dispositive power over such shares. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:06 UTC | IMMUNIC, INC. IMUX · Entity 6306 | SaleCommon Stock | 5,000 | $14.44 | $72,200.50 |
DisclosureSEC source: 0001193805-20-000880 · e619747_4-groppel.xml · nonDerivative · entry 1 Groeppel Manfred · CIK 0001773674 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 279,480 F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted in connection with certain tax liabilities related to the issuance of shares in the April 2019 exchange transaction between the Issuer (then known as Vital Therapies, Inc.) and Immunic AG. F2 · ownership.nature: The Reporting Person is Director of Groeppel Investments UG (haftungsbeschrankt), which is the record holder of 278,830 shares of common stock of the Issuer, and exercises voting and dispositive power over such shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:15 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000794 · e619747_4-groppel.xml · derivative · entry 1 Groeppel Manfred · CIK 0001773674 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: 7,500 of the shares underlying the option (the "Underlying Shares") vest on the one-year anniversary of the grant date. Thereafter, 625 of the Underlying Shares vest on each successive one-month anniversary thereafter for the next thirty six (36) months. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 12:45 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001193805-19-000702 · e618583_4-groppel.xml · derivative · entry 1 Groeppel Manfred · CIK 0001773674 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-08-01 F1 · derivative.exercise_date: 5,000 of the options vest on the one-year anniversary of the grant date. Thereafter, 440 of the options vest on the thirteen (13) month anniversary of the grant date, and 416 of the options vest on each successive one-month anniversary thereafter for the next thirty five (35) months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.